Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

PURPOSE: MLN8237, a selective small-molecule inhibitor of Aurora kinase A, has activity in a broad range of preclinical pediatric cancer models. We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic prope...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mossé, Yael P., Lipsitz, Emily, Fox, Elizabeth, Teachey, David T., Maris, John M., Weigel, Brenda, Adamson, Peter C., Ingle, Mark A., Ahern, Charlotte H., Blaney, Susan M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008248/
https://ncbi.nlm.nih.gov/pubmed/22988055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3251
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky